ArticleCancers2026
Inhibition of IGF1R in Early MMTV-Wnt1 Mammary Tumors: A Transcriptomic Analysis.
Joseph J Bulatowicz, Alexander Lemenze, Elvan Dogan, Christopher A Galifi, Krystopher Maingrette, Quan Shang, Teresa L Wood
Abstract read
In one paragraphArticle in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Joseph J BulatowiczDepartment of Pharmacology, Physiology, & Neuroscience, Center for Cell Signaling, Cancer Institute of New Jersey, New Jersey Medical School, Rutgers Health, Newark, NJ 07103, USA.
Alexander LemenzeMolecular and Genomics Informatics Core (MaGIC), New Jersey Medical School, Rutgers Health, Newark, NJ 07103, USA.
Elvan DoganDepartment of Pharmacology, Physiology, & Neuroscience, Center for Cell Signaling, Cancer Institute of New Jersey, New Jersey Medical School, Rutgers Health, Newark, NJ 07103, USA.ORCID 0000-0003-1561-2547 Christopher A GalifiDepartment of Pharmacology, Physiology, & Neuroscience, Center for Cell Signaling, Cancer Institute of New Jersey, New Jersey Medical School, Rutgers Health, Newark, NJ 07103, USA.
Krystopher MaingretteDepartment of Pharmacology, Physiology, & Neuroscience, Center for Cell Signaling, Cancer Institute of New Jersey, New Jersey Medical School, Rutgers Health, Newark, NJ 07103, USA.ORCID 0000-0001-5027-7188 Quan ShangDepartment of Pharmacology, Physiology, & Neuroscience, Center for Cell Signaling, Cancer Institute of New Jersey, New Jersey Medical School, Rutgers Health, Newark, NJ 07103, USA.
Teresa L WoodDepartment of Pharmacology, Physiology, & Neuroscience, Center for Cell Signaling, Cancer Institute of New Jersey, New Jersey Medical School, Rutgers Health, Newark, NJ 07103, USA.ORCID 0000-0002-4480-660X Funding
National Instututes of Health R01CA204312New Jersey Commission on Cancer Research COCR23RBG003Rutgers University Rutgers Biomedical Health Bridge
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
differentiationIGF1RkeratinmetastasisscRNA-seqsignalingWnt1
Identifiers
PMID42279332
PMCPMC13256066
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390